Evidence mapPaperPMID 41160271Full record

ReviewCurrent treatment options in oncology2025

Studies on the Critical Therapeutic Role of Artemisinin and its Derivatives in Melanoma: a Review of Preclinical Evidence.

E Liu, SiXian Bai, Ying Huang, Yaobin Pang, XueEr Zhang, Jinhao Zeng, Jing Guo

Abstract readReview
In one paragraph

Review in Current treatment options in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Potential Cosmetic Applications of Dihydroartemisinin.Molecules (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

E LiuChengdu University of Traditional Chinese Medicine, Chengdu, China.
SiXian BaiChengdu University of Traditional Chinese Medicine, Chengdu, China.
Ying HuangChengdu University of Traditional Chinese Medicine, Chengdu, China.
Yaobin PangChengdu University of Traditional Chinese Medicine, Chengdu, China.
XueEr ZhangChengdu University of Traditional Chinese Medicine, Chengdu, China.
Jinhao ZengTCM Prevention and Treatment of Metabolic and Chronic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Jing GuoDermatological Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. guojing66@cdutcm.edu.cn.

Funding

Chengdu University of Traditional Chinese Medicine "Apricot Grove Scholars" Discipline Talent Research Enhancement Program QJJJ2021001Chengdu University of Traditional Chinese Medicine "Foundation Thickening" Action Plan 2023-42Joint Innovation Fund of Health Commission of Chengdu and Chengdu University of Traditional Chinese Medicine WXLH202403001Sichuan Provincial Administration of Traditional Chinese Medicine 2021MS307Sichuan Provincial Administration of Traditional Chinese Medicine Scientific Research Special Project 2024zd027Sichuan Provincial Centralized Guided Local Science and Technology Development Special Project 2024ZYD0120Sichuan Provincial Health Commission Science and Technology Project"(24LCYJPT14) ;"Sichuan Provincial Administration of Traditional Chinese Medicine Science and Technology Research Special Project 2022CP1423Young Qihuang Scholars" of the State Administration of Traditional Chinese Medicine 2022-256
6 · The paper itself

Abstract

opinion statementAs a type of skin cancer, melanoma is characterized by a high rate of recurrence and metastasis, making it one of the leading causes of mortality associated with skin cancer. With the continuous advancement in technology, current treatment options for melanoma and metastatic melanoma have significantly improved; however, the threat posed by melanoma still warrants attention from the broader population. Artemisinin, derived from the plant Artemisia annua, is recognized as a promising drug molecule that demonstrates effective activity against both malaria and cancer. In this study, artemisinin and its derivatives (such as artemisinic acid, artesunate, and dihydroartemisinin) were shown to possess inhibitory effects on melanoma and ocular melanoma Further investigations revealed that the efficacy of these compounds is primarily linked to their ability to reduce melanin content, inhibit melanogenesis and cellular proliferation, suppress tumor growth in murine models, counteract tumor metastasis and angiogenesis, as well as promote apoptosis. The core mechanisms underlying these effects may be associated with signaling pathways such as PI3K/AKT/mTOR, MALAT918/YAP, along with those related to angiogenesis. In this study, we reviewed the inhibition of melanoma angiogenesis by natural products and its potential mechanisms using literature from PubMed, EMBASE, Web of Science, Ovid, ScienceDirect, Geenmedica, Cochrane Library and China National Knowledge Infrastructure databases. The search timeframe spans from the inception of the database to September 2025. Inclusion criteria encompass original English-language research articles, clinical trials, case reports, and relevant reviews focusing on the mechanisms, efficacy, or clinical applications of artemisinin derivatives in melanoma and ocular melanoma. Exclusion criteria include non-English literature, studies not directly related to melanoma, ocular melanoma, or the antitumour effects of artemisinin, and inaccessible Chinese-language literature. We additionally identified supplementary eligible studies through manual screening of reference lists from relevant literature.This study emphasizes the critical role of artemisinin and its derivatives in combating melanoma and ocular melanoma. The aim is to facilitate further development and utilization of these compounds while providing relevant insights for clinical research endeavors.

Indexed as

Antineoplastic AgentsArtemisininsMelanomaSkin NeoplasmsAnimalsHumansSignal TransductionAntineoplastic AgentsartemisininArtemisininsArtemisinic acidArtemisininArtesunateDihydroartemisininMelanomaMetastatic melanoma

Identifiers

PMID41160271
PMCPMC12634789

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.